Combinati |Q| SARS-CoV-2 Triplex Assay for sensitive detection of viral RNA targets
The COVID-19 pandemic has drawn heightened concern, with over eleven million positive SARS-CoV-2 cases confirmed worldwide by July 2020. 1 RT-qPCR currently serves as the clinical standard for the diagnosis of COVID-19.
Combinati believes simplicity shouldn’t require sacrificing robustness, quality, or rigor – in fact, it should enable it. Our easy-to-use digital PCR platform offers absolute quantification to track disease-relevant biomarkers over time with high accuracy and precision. Our core microfluidic technology, single instrument, and single consumable together enable consistent partitioning of samples with minimal sample waste.
Combined with the ability to robustly reject false positives and easily adapt traditional qPCR assays, Combinati aims to democratize digital PCR for researchers all over the world.
For research use only. Not for use in diagnostic procedures.